Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2017 16:05 ET | Source: KemPharm

KemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone

US Patent and Trademark Office issues patent protection to KP746, an investigational therapy for the treatment of pain with a prodrug of oxymorphone CORALVILLE, Iowa, June 26, 2017 (GLOBE NEWSWIRE)...
June 09, 2017 07:30 ET | Source: KemPharm

KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids

Poster Presentation Highlights Intranasal Abuse Deterrence Technology CORALVILLE, Iowa, June 09, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical...
June 01, 2017 07:30 ET | Source: KemPharm

KemPharm Announces Addition to Leadership Team

Andrew Barrett, Ph.D., appointed Vice President, Scientific Affairs CORALVILLE, Iowa, June 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical...
May 10, 2017 16:05 ET | Source: KemPharm

KemPharm, Inc. Reports First Quarter 2017 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ETClinical Development & Regulatory Highlights:Reported Positive Data from Proof-of-Concept Phase 1...
May 01, 2017 07:30 ET | Source: KemPharm

KemPharm, Inc. to Report First Quarter 2017 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled forMay 10, 2017, 4:30 p.m. ET CORALVILLE, Iowa, May 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a...
March 27, 2017 07:30 ET | Source: KemPharm

KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum

CORALVILLE, Iowa, March 27, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,...
March 16, 2017 07:30 ET | Source: KemPharm

KemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting

Poster Presentations Highlight Oral Equivalency and Intranasal Abuse Deterrence Technology CORALVILLE, Iowa, March 16, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage...
March 09, 2017 16:05 ET | Source: KemPharm

KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Recent Clinical Development & Regulatory Highlights: Reported Positive Data from Phase 1...
February 28, 2017 07:30 ET | Source: KemPharm

KemPharm, Inc. to Report Fourth Quarter and Year End 2016 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for March 9th, 2017, 4:30 p.m. ET CORALVILLE, Iowa, Feb. 28, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a...
February 23, 2017 07:30 ET | Source: KemPharm

KemPharm Announces Additional Patent Protection for Prodrug Portfolio

US Patent and Trademark Office decision extends additional patent protection to KP201 and the KP511 compound family CORALVILLE, Iowa, Feb. 23, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH),...